Table 2 HRQL impact of psoriasis at baseline: study population versus general US population
| Â | Adalimumab Mean (SD)1 | Placebo Mean (SD)2 | General US Population3 Mean (SD) |
|---|---|---|---|
Physical Functioning | 48.6 (10.3) | 48.2(10.6) | 49.4 (10.0) |
Role-Physical | 48.2 (11.1) | 48.7 (10.8) | 50.1 (9.9) |
Bodily Pain | 47.5 (10.9) | 47.4 (10.6) | 49.2 (10.2) |
General Health | 49.5 (9.5) | 50.2 (9.5) | 49.3 (10.7) |
Vitality | 49.9 (9.8) | 50.3 (10.3) | 50.4 (10.5) |
Social Functioning | 46.0 (11.8) | 46.1 (11.7) | 50.1 (10.1) |
Role-Emotional | 47.6 (12.0) | 47.4 (12.0) | 50.6 (9.5) |
Mental Health | 47.4 (10.8) | 47.9 (11.0) | 49.4 (10.7) |